{"id":43820,"date":"2024-03-04T10:20:00","date_gmt":"2024-03-04T15:20:00","guid":{"rendered":"https:\/\/www.parkinson.ca\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/"},"modified":"2024-11-22T13:29:52","modified_gmt":"2024-11-22T18:29:52","slug":"vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada","status":"publish","type":"post","link":"https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/","title":{"rendered":"VYALEV (solution de foslevodopa\/foscarbidopa) est maintenant disponible au Canada."},"content":{"rendered":"<p><span data-contrast=\"auto\">Une nouvelle option de traitement pour la maladie de Parkinson avanc\u00e9e est maintenant disponible sous le nom de VYALEV.\u00a0 Ce traitement est le premier et le seul traitement par perfusion sous-cutan\u00e9e (sous la peau) de 24 heures \u00e0 base de l\u00e9vodopa au Canada, pour la prise en charge des fluctuations motrices s\u00e9v\u00e8res et de l&rsquo;hyper-\/dyskin\u00e9sie.\u00a0\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><strong>\u00c0 propos de <\/strong><span data-contrast=\"auto\"><strong>VYALEV<\/strong>\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">VYALEV (foslevodopa\/foscarbidopa) est une solution de l\u00e9vodopa et de carbidopa en perfusion sous-cutan\u00e9e continue pour le traitement de la maladie de Parkinson \u00e0 un stade avanc\u00e9 chez les patients qui ne contr\u00f4lent pas leurs sympt\u00f4mes moteurs. Ces sympt\u00f4mes sont souvent trait\u00e9s par des m\u00e9dicaments oraux. Au fur et \u00e0 mesure de l&rsquo;\u00e9volution de la maladie de Parkinson, les traitements oraux peuvent perdre de leur efficacit\u00e9.\u00a0\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">VYALEV est une th\u00e9rapie assist\u00e9e par un dispositif qui d\u00e9livre en continu le m\u00e9dicament dont ils ont besoin. Dans le pass\u00e9, les th\u00e9rapies assist\u00e9es par dispositif n\u00e9cessitaient g\u00e9n\u00e9ralement une intervention chirurgicale. Avec l&rsquo;introduction d&rsquo;une solution sous-cutan\u00e9e telle que VYALEV, certaines personnes atteintes de la maladie de Parkinson \u00e0 un stade avanc\u00e9 ont d\u00e9sormais acc\u00e8s \u00e0 un traitement assist\u00e9 qui est beaucoup moins invasif.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Cette option non chirurgicale repr\u00e9sente un progr\u00e8s dans la gestion des sympt\u00f4mes et r\u00e9pond \u00e0 un besoin non satisfait au sein de la communaut\u00e9 des malades de Parkinson. \u00ab\u202fPersonne ne vit la maladie de Parkinson de la m\u00eame mani\u00e8re, c&rsquo;est pourquoi il est essentiel que les personnes atteintes de la maladie aient acc\u00e8s \u00e0 des options qui les aideront \u00e0 g\u00e9rer leurs sympt\u00f4mes \u00e0 tous les stades de la maladie. Cette annonce donne l&rsquo;espoir aux personnes atteintes de la maladie de Parkinson qu&rsquo;elles auront acc\u00e8s \u00e0 plus d&rsquo;options pour les aider \u00e0 g\u00e9rer leur maladie, m\u00eame aux stades avanc\u00e9s\u202f\u00bb, a d\u00e9clar\u00e9 Karen Lee, pr\u00e9sidente-directrice g\u00e9n\u00e9rale de Parkinson Canada.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Acc\u00e8s \u00e0 VYALEV [Mis \u00e0 jour le 22 novembre 2024]<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Vyalev a \u00e9t\u00e9 ajout\u00e9 \u00e0 la liste des m\u00e9dicaments rembours\u00e9s par l&rsquo;\u00c9tat dans les provinces suivantes : <\/span><a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fidbl.ab.bluecross.ca%2Fidbl%2FDBL%2Fjun_dblupdate.pdf&amp;data=05%7C02%7CSally.Adam%40Parkinson.ca%7Cb5504327606f4a35e6ca08dcc201654f%7C793936678b374886a4b4b9ef6b83c026%7C0%7C0%7C638598558453698807%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=xep4Tli5gXLlraJ%2B%2FH9vuIVhkxqOcB9HH8hpITxAeAo%3D&amp;reserved=0\"><span data-contrast=\"none\">Alberta<\/span><\/a><span data-contrast=\"auto\">, <\/span><a href=\"https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/pharmacare\/programs\/limited-coverage-drug-program\/limited-coverage-drugs-foslevodopa-foscarbidopa\"><span data-contrast=\"none\">Colombie-Britannique, <\/span><\/a><a href=\"https:\/\/www.gov.mb.ca\/health\/mdbif\/docs\/bulletins\/bulletin133.pdf\"><span data-contrast=\"none\">Manitoba, <\/span><\/a><a href=\"https:\/\/www2.gnb.ca\/content\/dam\/gnb\/Departments\/h-s\/pdf\/en\/NBDrugPlan\/FormularyUpdates\/nb-drug-plans-bulletin-1143.pdf\"><span data-contrast=\"none\">Nouveau-Brunswick<\/span><\/a><span data-contrast=\"auto\">, <a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fnovascotia.ca%2Fdhw%2Fpharmacare%2Fformulary.asp&amp;data=05%7C02%7CSally.Adam%40Parkinson.ca%7Cb5504327606f4a35e6ca08dcc201654f%7C793936678b374886a4b4b9ef6b83c026%7C0%7C0%7C638598558453718439%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=JvHO4iztbPJkh5JVq%2FcgGD0%2BNflXL2dm2ohDxX%2FFSnU%3D&amp;reserved=0\">Nouvelle-\u00c9cosse,<\/a> Ontario, <a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.ramq.gouv.qc.ca%2Fen%2Fabout-us%2Flist-medications&amp;data=05%7C02%7CSally.Adam%40Parkinson.ca%7Cb5504327606f4a35e6ca08dcc201654f%7C793936678b374886a4b4b9ef6b83c026%7C0%7C0%7C638598558453685803%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=wagPKoQIpU3XjuCKS4H6MTWXtMbPRy2zzTZWK10%2B1qw%3D&amp;reserved=0\">Qu\u00e9bec<\/a>, <a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fformulary.drugplan.ehealthsask.ca%2FSearchFormulary&amp;data=05%7C02%7CSally.Adam%40Parkinson.ca%7Cb5504327606f4a35e6ca08dcc201654f%7C793936678b374886a4b4b9ef6b83c026%7C0%7C0%7C638598558453710338%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=49iNyzOaw3YqwRC90qAqbnMydUbEo%2FJgPUmbJ2xSXMo%3D&amp;reserved=0\">Saskatchewan<\/a>, <a href=\"https:\/\/www.hss.gov.nt.ca\/en\/services\/nt-pharmacare-formulary\">Territoires du Nord-Ouest<\/a> et <\/span><a href=\"https:\/\/nlpdp.bell.ca\/\"><span data-contrast=\"none\">Terre-Neuve et Labrador.<\/span><\/a><\/p>\n<p><span data-contrast=\"auto\">Chaque province d\u00e9cide des m\u00e9dicaments \u00e0 inclure dans son r\u00e9gime public d&rsquo;assurance-m\u00e9dicaments. Pour les membres de la communaut\u00e9 de la maladie de Parkinson qui r\u00e9sident dans des provinces et territoires autres que les provinces \u00e9num\u00e9r\u00e9es ci-dessus, la couverture de VYALEV est pour l&rsquo;instant limit\u00e9e aux personnes qui ont une assurance maladie priv\u00e9e et aux payeurs priv\u00e9s.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">La rapidit\u00e9 de ces approbations dans ces provinces est encourageante. Mais nous savons que cela laisse de nombreux membres de notre communaut\u00e9 dans l&rsquo;expectative. Nous esp\u00e9rons que les autres provinces et territoires agiront \u00e9galement rapidement pour ajouter VYALEV \u00e0 leurs r\u00e9gimes publics d&rsquo;assurance-m\u00e9dicaments respectifs. Parkinson Canada continuera de faire entendre la voix de sa communaut\u00e9 pour assurer un acc\u00e8s large et \u00e9quitable \u00e0 tous les Canadiens atteints de la maladie de Parkinson qui pourraient b\u00e9n\u00e9ficier de ce traitement.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Si vous \u00eates une personne atteinte de la maladie de Parkinson, vous devriez consulter votre fournisseur de soins de sant\u00e9 avant de modifier votre plan de traitement.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Pour des informations compl\u00e8tes sur VYALEV, la monographie du produit est disponible <\/span><a href=\"https:\/\/www.abbvie.ca\/content\/dam\/abbvie-dotcom\/ca\/fr\/documents\/products\/VYALEV_PM_FR.pdf\"><span data-contrast=\"none\">ici.<\/span><\/a><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Une nouvelle option de traitement pour la maladie de Parkinson avanc\u00e9e est maintenant disponible sous le nom de VYALEV.\u00a0 Ce &#8230; <a href=\"https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/\" class=\"more-link\">En savoir plus<\/a><\/p>\n","protected":false},"author":82,"featured_media":43823,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[209,64,140],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>VYALEV (solution de foslevodopa\/foscarbidopa) est maintenant disponible au Canada. - Parkinson Canada<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VYALEV (solution de foslevodopa\/foscarbidopa) est maintenant disponible au Canada. - Parkinson Canada\" \/>\n<meta property=\"og:description\" content=\"Une nouvelle option de traitement pour la maladie de Parkinson avanc\u00e9e est maintenant disponible sous le nom de VYALEV.\u00a0 Ce ... En savoir plus\" \/>\n<meta property=\"og:url\" content=\"https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/\" \/>\n<meta property=\"og:site_name\" content=\"Parkinson Canada\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/parkinsoncanada\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-04T15:20:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-22T18:29:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/archiveparkinson.thedev.ca\/wp-content\/uploads\/VYALEV-solution-de-foslevodopafoscarbidopa-est-maintenant-disponible-au-Canada..png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mikaela Derksen\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ParkinsonCanada\" \/>\n<meta name=\"twitter:site\" content=\"@ParkinsonCanada\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mikaela Derksen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/\",\"url\":\"https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/\",\"name\":\"VYALEV (solution de foslevodopa\/foscarbidopa) est maintenant disponible au Canada. - Parkinson Canada\",\"isPartOf\":{\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/#website\"},\"datePublished\":\"2024-03-04T15:20:00+00:00\",\"dateModified\":\"2024-11-22T18:29:52+00:00\",\"author\":{\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/#\/schema\/person\/6650a86d605ef0b6b183826bc4c613f8\"},\"breadcrumb\":{\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/archiveparkinson.thedev.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VYALEV (solution de foslevodopa\/foscarbidopa) est maintenant disponible au Canada.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/#website\",\"url\":\"https:\/\/archiveparkinson.thedev.ca\/\",\"name\":\"Parkinson Canada\",\"description\":\"Empowering the Parkinson&#039;s community across Canada\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/archiveparkinson.thedev.ca\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/#\/schema\/person\/6650a86d605ef0b6b183826bc4c613f8\",\"name\":\"Mikaela Derksen\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3e000bf17e14ea99fc1ae56bcdc3aa18?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3e000bf17e14ea99fc1ae56bcdc3aa18?s=96&d=mm&r=g\",\"caption\":\"Mikaela Derksen\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VYALEV (solution de foslevodopa\/foscarbidopa) est maintenant disponible au Canada. - Parkinson Canada","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"VYALEV (solution de foslevodopa\/foscarbidopa) est maintenant disponible au Canada. - Parkinson Canada","og_description":"Une nouvelle option de traitement pour la maladie de Parkinson avanc\u00e9e est maintenant disponible sous le nom de VYALEV.\u00a0 Ce ... En savoir plus","og_url":"https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/","og_site_name":"Parkinson Canada","article_publisher":"https:\/\/www.facebook.com\/parkinsoncanada\/","article_published_time":"2024-03-04T15:20:00+00:00","article_modified_time":"2024-11-22T18:29:52+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/archiveparkinson.thedev.ca\/wp-content\/uploads\/VYALEV-solution-de-foslevodopafoscarbidopa-est-maintenant-disponible-au-Canada..png","type":"image\/png"}],"author":"Mikaela Derksen","twitter_card":"summary_large_image","twitter_creator":"@ParkinsonCanada","twitter_site":"@ParkinsonCanada","twitter_misc":{"\u00c9crit par":"Mikaela Derksen","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/","url":"https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/","name":"VYALEV (solution de foslevodopa\/foscarbidopa) est maintenant disponible au Canada. - Parkinson Canada","isPartOf":{"@id":"https:\/\/archiveparkinson.thedev.ca\/#website"},"datePublished":"2024-03-04T15:20:00+00:00","dateModified":"2024-11-22T18:29:52+00:00","author":{"@id":"https:\/\/archiveparkinson.thedev.ca\/#\/schema\/person\/6650a86d605ef0b6b183826bc4c613f8"},"breadcrumb":{"@id":"https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/archiveparkinson.thedev.ca\/fr\/vyalev-solution-de-foslevodopa-foscarbidopa-est-maintenant-disponible-au-canada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/archiveparkinson.thedev.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"VYALEV (solution de foslevodopa\/foscarbidopa) est maintenant disponible au Canada."}]},{"@type":"WebSite","@id":"https:\/\/archiveparkinson.thedev.ca\/#website","url":"https:\/\/archiveparkinson.thedev.ca\/","name":"Parkinson Canada","description":"Empowering the Parkinson&#039;s community across Canada","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/archiveparkinson.thedev.ca\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/archiveparkinson.thedev.ca\/#\/schema\/person\/6650a86d605ef0b6b183826bc4c613f8","name":"Mikaela Derksen","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/archiveparkinson.thedev.ca\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3e000bf17e14ea99fc1ae56bcdc3aa18?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e000bf17e14ea99fc1ae56bcdc3aa18?s=96&d=mm&r=g","caption":"Mikaela Derksen"}}]}},"_links":{"self":[{"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/posts\/43820"}],"collection":[{"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/users\/82"}],"replies":[{"embeddable":true,"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/comments?post=43820"}],"version-history":[{"count":3,"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/posts\/43820\/revisions"}],"predecessor-version":[{"id":43827,"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/posts\/43820\/revisions\/43827"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/media\/43823"}],"wp:attachment":[{"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/media?parent=43820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/categories?post=43820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/tags?post=43820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}